Beta Bionics’ iLet bionic pancreas offers insulin therapy without some of the hurdles associated with treating diabetes.
Users of insulin pumps may be used to a certain regimen associated with managing their diabetes. That can include carbohydrate counting, setting basal rates and more.
Beta Bionics has set out to change that. With the Concord, Massachusetts-based company’s iLet bionic pancreas, the user inputs just one number: their body weight.
The company designed the pocket-sized, wearable, investigational iLet device to autonomously dose insulin. Worn like an insulin pump, iLet users only enter body weight to initialize therapy without the need for insulin regimen parameters. The company designed the device to then automatically titrate and infuse insulin without requiring the counting of carbs, the settings of certain rates and factors and more.
“It’s very qualitative, not quantitative,” Beta Bionics interim CEO and board member Martha Aronson told Drug Delivery Business News. “This cognitive burden — the amount of math you have to do every day if you’re a person with type one diabetes — is extraordinary. Our goal is to take away that cognitive burden for people who live with type one diabetes.”